Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | How will the PARADIGM trial change the mCRC treatment landscape?

The phase III PARADIGM study (NCT02394795) recently demonstrated the efficacy of panitumumab plus mFOLFOX6 in patients with RAS wildtype metastatic colorectal cancer (mCRC). Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, comments on the consequences of the trial findings. Anti-EFGR therapies such as panitumumab should become the standard of care as a first line therapy for RAS wildtype mCRC. However, the current regimen of bevacizumab with mFOLFOX6 may be given to patients if there are concerns with toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.